Fundraising FoxKayoThera
Seattle, US · Founded 2019 · 3 known investors
Find your way into KayoThera
Each arrow is one introduction. Sign up to fill in the first one.
462 people can intro you to Mark
Ask Paul Sekhri to introduce you to Mark Esposito
You →Paul · together at KayoThera →Mark
Sign up to find every way you can get introduced to KayoThera
- Your email: who you already know at KayoThera, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the KayoThera team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
Founders & leadership
KayoThera was founded in 2019 by Mark Esposito and Yibin Kang.
ME
Mark EspositoCSO, Co-Founder and Board MemberMark Esposito is Chief Scientific Officer and co-founder of Kayo Therapeutics, a biotechnology company developing therapeutics targeting metabolic disease and oncology. He has worked as a consultant to the biotech and pharmaceutical industry.
YK
Yibin KangChair, Scientific Advisory Board and Co-Founder
KM
Kendall MohlerExecutive
TQ
Thong Q. LePresident and CEO, Board Member
IH
Ian HowesChief Financial Officer
Investors · 3
Funding
SEC filings, press & company announcements$11.2M disclosed across 2 of 3 rounds · 2019–2023
- Undisclosed amountSeries AJul 2023Source ↗
▶$10.5MraisedJul 2023 · 14 investors · OtherRule 506(b)
▶$10.5MraisedJul 2023 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Thong LeExecutive Officer, Director
- Mark EspositoExecutive Officer, Director
- Kendall MohlerExecutive Officer, Director
- Ian HowesExecutive Officer
- Offering amount
- $10.9M
- Amount sold
- $10.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$750KraisedJun 2019 · 1 investors · OtherRule 506(b)
▶$750KraisedJun 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mark EspositoExecutive Officer, Director
- Yibin KangDirector
- George F. HeinrichDirector
- James M. GolubieskiDirector
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
SonoTheraSonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.
AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
RayTheraA biopharmaceutical company developing therapies for neurology, immunology, and rare diseases. The page describes work focused on treating hard-to-treat conditions.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies working in the same space as KayoThera.
Frequently asked questions
- What does KayoThera do?
- Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
- Who founded KayoThera?
- KayoThera was founded by Mark Esposito, Yibin Kang in 2019.
- Who are KayoThera's investors?
- KayoThera's investors include 7G BioVentures, BioAdvance, Foundation Venture Capital Group, LLC.
- How much funding has KayoThera raised?
- KayoThera has disclosed $11.2M raised across 2 of its 3 known rounds.
- Where is KayoThera headquartered?
- KayoThera is headquartered in Seattle, US.